Santarus Inc. (SNTS: Quote) announced after the close Monday that it received FDA approval for UCERIS extended release tablets, for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Santarus gapped open sharply higher Tuesday, but was range-bound throughout the session. The stock closed up by 1.24 at $12.52 on the highest volume of the year. Santarus rose above nearly a 2-week range and set a new high for the year.
Click here to receive FREE breaking news email alerts for Santarus Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News